- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Triplet Therapy Plus Transplantation Prolongs PFS in Multiple Myeloma
August 08, 2022
With a median progression-free survival of 46.2 months in the RVD-alone group and 67.5 months in the transplantation group, lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation extends overall survival in patients with newly diagnosed multiple myeloma.
PARP Inhibitor Regimen Leads to Promising ORR in ES-SCLC
August 08, 2022
The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.
Expert Compares Atezolizumab and Durvalumab as Therapy for ES-SCLC
August 08, 2022
During a live virtual event, Benjamin P. Levy, MD, discussed the results of the IMpower 133 and CASPIAN trials of immunotherapy for patients with extensive-stage small cell lung cancer.
Promising ORR Seen With Temozolomide Plus Nivolumab in Previously-Treated ES-SCLC
August 08, 2022
The combination of temozolomide and nivolumab demonstrated promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.
New Strategies Needed for Patients With NSCLC Who Progress on Chemoimmunotherapy
August 08, 2022
Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.
Paxalisib Plus Radiotherapy Reveals Promising ORR in Patients With Brain Metastases
August 08, 2022
The combination of paxalisib and radiotherapy exhibited complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial.
EGFR C797X Becomes Leading Mechanism Following Osimertinib in NSCLC
August 08, 2022
Following treatment osimertinib, EGFR C797X mutations are now the leading mechanism of acquired resistance, outpacing MET amplification.
Amivantamab Plus Lazertinib and Chemo Elicits Encouraging ORR in Pretreated EGFR-Mutant NSCLC
August 08, 2022
Amivantamab in combination with lazertinib and chemotherapy combination demonstrated encouraging responses in EGFR-mutant non–small cell lung cancer.
Anticipating Expanded Uses of Radiotherapy in Urothelial Carcinoma
August 08, 2022
Sophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.
Neoadjuvant Chemoimmunotherapy Shows Significant Survival Benefit in Stage III NSCLC
August 08, 2022
Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.
Treatment Options for AML Patients with IDH2, RUNX1, or DNMT3A Mutations
August 08, 2022
Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies
August 08, 2022
Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.